Chip stocks fall with Nvidia after data center rev disappointment
On Friday, Leerink Partners adjusted their financial outlook on ANI Pharmaceuticals (NASDAQ:ANIP), increasing the price target to $82.00 from the previous $80.00 while maintaining an Outperform rating on the company’s shares. According to InvestingPro data, analyst targets for ANIP range from $62 to $94, with the company maintaining a GREAT financial health score of 3.04 out of 5. The revision follows ANI Pharmaceuticals’ announcement of their fourth-quarter financial results, which exhibited performance surpassing their prior top and bottom line pre-announcement. With impressive revenue growth of 23.6% and an EBITDA of $82.12 million in the last twelve months, the company has revised its 2025 revenue and adjusted EBITDA guidance upwards and provided new segment-specific forecasts, particularly emphasizing a strong projection for Cortrophin Gel. InvestingPro analysis reveals 8 additional key insights about ANIP’s financial position and growth prospects.
ANI Pharmaceuticals has recently shared their full-year 2024 financial results, which exceeded expectations. The company’s management has shown confidence by already adjusting the 2025 guidance, signaling a positive outlook for the future. Leerink Partners have highlighted the potential growth of Cortrophin Gel, a key product for ANI Pharmaceuticals, as a primary interest. Additionally, the growth of Iluvien/Yutiq is noted as an area to watch, as the company progresses with its commercial strategy after acquiring these products in September.
The company anticipates launching a pre-filled syringe formulation of Cortrophin Gel in the second quarter of 2025, a slight adjustment from the broader first half of 2025 window previously expected. Furthermore, ANI Pharmaceuticals is preparing to present data from the New Day and Synchronicity studies related to Iluvien and Yutiq, respectively, also in the second quarter of 2025.
Leerink Partners has expressed a belief that the market may not fully recognize the transformation of ANI Pharmaceuticals. The company is shifting from its legacy as a generic drug manufacturer to a more focused entity specializing in branded rare disease products, supported by a strong balance sheet with a current ratio of 2.74 and market capitalization of $1.21 billion. The optimistic outlook for Cortrophin Gel and the strategic growth of Iluvien/Yutiq are central to this evolution, with management providing insights into the commercial dynamics at play for these products. For a comprehensive analysis of ANIP’s transformation and future prospects, access the detailed Pro Research Report available on InvestingPro, which provides expert insights on over 1,400 US stocks.
In other recent news, ANI Pharmaceuticals reported impressive fourth-quarter earnings that exceeded analyst expectations, prompting a significant rise in its stock. The company achieved adjusted earnings per share of $1.63, surpassing the analyst estimate of $1.45, and reported revenue of $190.6 million, which was higher than the projected $175.12 million. This revenue marks a 44.8% increase compared to the previous year. A key driver of this growth was ANI’s Rare Disease segment, which saw revenue more than double, reaching $87 million. This included substantial contributions from Cortrophin Gel and newly acquired ophthalmology drugs ILUVIEN and YUTIQ.
In light of these strong results, ANI Pharmaceuticals raised its full-year 2025 guidance, now expecting revenue between $756 million and $776 million, which is above the previous forecast and analyst consensus. The company also introduced an adjusted EPS guidance of $6.12 to $6.49, exceeding the analyst estimate of $5.56. The positive outlook is attributed to the ongoing momentum in the Cortrophin Gel business and successful integration of its new ophthalmology franchise. These developments reflect ANI’s expectation that Rare Disease net revenues will account for 48% to 49% of total company revenues in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.